

Applicants: Jeffers et al  
U.S.S.N.: 09/609,543

"Sequence Listing," an initial paper copy of the "Sequence Listing," and a statement that the content of the paper and computer readable copies are the same and include no new matter, in compliance with 37 C.F.R. §§ 1.821-1.825. The specification has been amended to insert the sequence listing.


In the original application, SEQ ID NOs were not applied to the nucleotide or amino acid sequences in Figures 5 and 13. The assigned SEQ ID NOs now correspond to the sequences in the sequence listing. Applicants state that no new matter has been added.

### CONCLUSION

Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned **"Version with markings to show changes made."**

The Commissioner is authorized to charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Attorney Reference No. 15966-557 CIP1 (Cura-57 CIP1).

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,579

Kristin E. Konzak, Reg. No. 44,848

Attorney/Agent for Applicant

c/o MINTZ, LEVIN, COHN, FERRIS  
GLOVSKY AND POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000

Fax: (617) 542-2241

DATE: August 8, 2001

**Version with markings to show changes made**

Amend the paragraph starting on page 7, line 1, as follows:

Figure 5 is a ClustalW alignment of FGF-CX with three other FGF family members. FGF-CX (SEQ ID NO:2) was aligned with human FGF-9 (SEQ ID NO:12), human FGF-16 (SEQ ID NO:9) and Xenopus FGF-CX (SEQ ID NO:24) (Accession Numbers D14838, AB009391 and AB012615, respectively).

Amend the paragraph starting on page 7, line 19, as follows:

Figure 13 presents an analysis of the FGF-CX gene (SEQ ID NO:25), including the nucleotide and deduced amino acid sequence (SEQ ID NO:2) of FGF-CX. The initiation and stop codons are in bold, and an in frame stop codon residing in the 5' UTR is underlined.

TRA 1552369v1